Cargando…
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay
BACKGROUND: This study assessed the Granzyme B (GrB) ELISPOT as a viable alternative to the (51)Cr-release assay for measuring cytotoxic activity of innate immune effector cells. We strategically selected the GrB ELISPOT assay because GrB is a hallmark effector molecule of cell-mediated destruction...
Autores principales: | Shafer-Weaver, Kimberly A, Sayers, Thomas, Kuhns, Douglas B, Strobl, Susan L, Burkett, Mark W, Baseler, Michael, Malyguine, Anatoli |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC522821/ https://www.ncbi.nlm.nih.gov/pubmed/15380049 http://dx.doi.org/10.1186/1479-5876-2-31 |
Ejemplares similares
-
The Granzyme B ELISPOT assay: an alternative to the (51)Cr-release assay for monitoring cell-mediated cytotoxicity
por: Shafer-Weaver, Kimberly, et al.
Publicado: (2003) -
A modified human ELISPOT assay to detect specific responses to primary tumor cell targets
por: Malyguine, Anatoli, et al.
Publicado: (2004) -
ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials
por: Malyguine, Anatoli M., et al.
Publicado: (2012) -
Modified ELISPOT: Modifications of the Elispot Assay for T Cell Monitoring in Cancer Vaccine Trials
por: Malyguine, Anatoli
Publicado: (2005) -
An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity
por: Barabas, Sascha, et al.
Publicado: (2017)